Abstract
During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Biphenyl Compounds / administration & dosage
-
Diabetes Mellitus, Type 2 / complications*
-
Diabetes Mellitus, Type 2 / diagnosis
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetes Mellitus, Type 2 / mortality
-
Diabetic Angiopathies / diagnosis*
-
Diabetic Angiopathies / mortality
-
Diabetic Nephropathies / diagnosis*
-
Diabetic Nephropathies / mortality
-
Electrocardiography*
-
Female
-
Follow-Up Studies
-
Humans
-
Hypertension / complications
-
Hypertension / diagnosis*
-
Hypertension / mortality
-
Incidence
-
Irbesartan
-
Male
-
Middle Aged
-
Myocardial Infarction / diagnosis*
-
Myocardial Infarction / etiology*
-
Myocardial Infarction / mortality
-
Prospective Studies
-
Risk Assessment
-
Severity of Illness Index
-
Survival Analysis
-
Tetrazoles / administration & dosage
-
Treatment Outcome
Substances
-
Biphenyl Compounds
-
Tetrazoles
-
Irbesartan